Academic Journal of Medicine & Health Sciences, 2024, 5(1); doi: 10.25236/AJMHS.2024.050116.
Gang Huang1, Yinzhu He2
1Huazhi Biotechnology Co. Ltd., Changsha, 410125, China
2Changsha BGI Meixi Lake Clinical Laboratory Co. Ltd, Changsha, 410125, China
Insulin resistance refers to a decreased sensitivity of target organs to insulin, leading to reduced uptake and utilization of glucose by the body, thereby causing hyperglycemia and metabolic syndrome. As the core pathophysiological mechanism of metabolic diseases such as type 2 diabetes, obesity, and cardiovascular diseases, insulin resistance poses a significant threat to global public health. Although both genetic and environmental factors are believed to be associated with the onset and development of insulin resistance, the specific pathogenic genes and their mechanisms of action are not yet fully clarified. With advances in life science technology, especially the rapid development of metagenomic sequencing, scientists have begun to explore the etiology of insulin resistance from the perspective of the gut microbiome. The gut microbiome is a complex ecosystem containing trillions of microbes, which form a mutually dependent and interactive microenvironment with the human body. The collective genome of these microbes, the metagenome, has a profound impact on human metabolism and immune function. In-depth research not only helps us to understand the pathogenesis of insulin resistance more comprehensively but also provides a scientific basis for developing new intervention measures and treatment strategies, contributing to the improvement of global public health.
Metagenomic Sequencing; Insulin Resistance; Pathogenic Genes
Gang Huang, Yinzhu He. Research on the Pathogenic Genes of Insulin Resistance Based on Metagenomic Sequencing. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 1: 103-107. https://doi.org/10.25236/AJMHS.2024.050116.
[1] Takeuchi, T., Kubota, T., Nakanishi, Y. et al. Gut microbial carbohydrate metabolism contributes to insulin resistance [J]. Nature621. 2023, 389–395.
[2] Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome [J]. Nature 414. 2001, 821–827.
[3] Thingholm, L. B. et al. Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition [J]. Cell Host Microbe 26. 2019, 252–264.
[4] Gou, W. et al. Interpretable machine learning framework reveals robust gut microbiome features associated with type 2 diabetes. Diabetes Care44. 2021, 358–366.
[5] Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity [J]. Nature 535. 2016, 376–381.